Last reviewed · How we verify
GYNODAKTARIN®
GYNODAKTARIN is an antifungal agent that disrupts fungal cell membrane integrity by inhibiting ergosterol synthesis.
GYNODAKTARIN is an antifungal agent that disrupts fungal cell membrane integrity by inhibiting ergosterol synthesis. Used for Vaginal candidiasis, Dermatophyte infections (tinea pedis, tinea corporis, tinea cruris).
At a glance
| Generic name | GYNODAKTARIN® |
|---|---|
| Sponsor | Laboratoire Innotech International |
| Drug class | Imidazole antifungal |
| Target | Lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The drug belongs to the imidazole class of antifungals and works by inhibiting the fungal cytochrome P450 enzyme lanosterol 14α-demethylase, which is essential for ergosterol production. Ergosterol is a critical component of the fungal cell membrane; its depletion leads to membrane instability, leakage, and ultimately fungal cell death. This mechanism makes it effective against various dermatophytes and Candida species.
Approved indications
- Vaginal candidiasis
- Dermatophyte infections (tinea pedis, tinea corporis, tinea cruris)
Common side effects
- Vulvovaginal irritation
- Burning sensation
- Local erythema
Key clinical trials
- Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GYNODAKTARIN® CI brief — competitive landscape report
- GYNODAKTARIN® updates RSS · CI watch RSS
- Laboratoire Innotech International portfolio CI